Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection

This publication has 36 references indexed in Scilit:

• A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
  AIDS, 2003
• Switching Effective Antiretroviral Therapy: A Review
  Clinical Infectious Diseases, 2002
• Low Risk of Treatment Failure after Substitution of Nevirapine for Protease Inhibitors among Human Immunodeficiency Virus–Infected Patients with Virus Suppression
  The Journal of Infectious Diseases, 2002
• Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression
  Clinical Infectious Diseases, 2002
• Efavirenz as a Substitute for Protease Inhibitors in HIV-1–Infected Patients With Undetectable Plasma Viral Load on HAART: A Median Follow-Up of 64 Weeks
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
• Switch to Efavirenz in a Protease Inhibitor-Containing Regimen
  HIV Research & Clinical Practice, 2001
• Substitution of a Nonnucleoside Reverse Transcriptase Inhibitor for a Protease Inhibitor in the Treatment of Patients with Undetectable Plasma Human Immunodeficiency Virus Type 1 RNA
  Clinical Infectious Diseases, 2000
• Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with Lipodystrophy
  Clinical Infectious Diseases, 2000
• Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
  New England Journal of Medicine, 1999
• Changing patterns of mortality across Europe in patients infected with HIV-1
  The Lancet, 1998